Physician profile
Teejay Tripp
NPI 1629308424
$14,539.05
in general payments reported to CMS, 2019-2025
35 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $876 · 2021: $2,153 · 2022: $2,345 · 2023: $2,800 · 2024: $2,788 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,606 · Education: $8.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,605.64 |
| Education | $8.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,714.86 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,520.05 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $1,189.12 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,143.42 | 2020-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $845.48 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $769.57 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $738.74 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $695.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $549.21 | 2019-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $534.33 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $523.74 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $494.21 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Almatica Pharma LLC | $490.96 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $438.68 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $410.39 | 2022-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $311.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $295.71 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $254.55 | 2019-2025 | Ingrezza |
| Eisai INC. | $222.81 | 2020-2022 | |
| Neos Therapeutics, LP | $159.33 | 2019-2023 | Adzenys Xr-Odt |
| Brainsway USA INC | $156.97 | 2019 | |
| Bausch Health US, LLC | $151.28 | 2019-2025 | Aplenzin |
| Neuronetics, INC. | $129.25 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $126.91 | 2023 | Quviviq |
| Biogen, INC. | $126.37 | 2024-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $82.60 | 2024-2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $76.05 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $64.48 | 2022-2025 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $64.00 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $62.43 | 2019-2025 | Relexxii |
| Shire North American Group INC | $59.30 | 2019 | |
| Adlon Therapeutics L.P. | $58.90 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $48.29 | 2021-2022 | |
| Tempus Ai, INC | $19.27 | 2024 | Tempus Pixel |
| Alfasigma USA, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teejay Tripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.